7210 Frederick-Banting
Suite 100
Montreal, QC H4S 2A1
Canada
https://www.reparerx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 158
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Lloyd Mitchell Segal | Pres, CEO & Director | 913.37k | 148.07k | 1964 |
Mr. Steve Forte | Exec. VP & CFO | 608.52k | N/A | 1979 |
Dr. Michael Zinda Ph.D. | Exec. VP & Chief Scientific Officer | 655.28k | 1.07M | 1971 |
Dr. Maria Koehler M.D., Ph.D. | Exec. VP & Chief Medical Officer | 669.83k | 892.97k | 1957 |
Dr. Daniel Durocher Ph.D. | Co-Founder | N/A | N/A | N/A |
Dr. Frank Sicheri Ph.D. | Co-Founder | N/A | N/A | N/A |
Dr. Agnel Sfeir Ph.D. | Co-Founder | N/A | N/A | N/A |
Dr. Kim A. Seth | Exec. VP and Head of Bus. & Corp. Devel. | N/A | N/A | N/A |
Mr. Cameron Black | Exec. VP of Discovery | N/A | N/A | N/A |
Mr. Philip Herman | Exec. VP of Commercial & New Product Devel. | N/A | N/A | 1980 |
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Repare Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.